CompletedNot Applicable

Study To Evaluate The Efficacy Of Tofacitinib In Patients With SJS/TEN

Taiwan20 participantsStarted 2022-08-01

Plain-language summary

The goal of this study is to evaluate the effect of tofacitinib in patients with Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). The primary outcome of the study is the time to complete re-epithelialization. The secondary outcomes are to determine mortality, length of hospitalization, adverse events, the time to beginning of epithelization, the time to halting of progression of SJS/TEN, ocular complications, and infections.

Who can participate

Age range20 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Willing to sign inform consent form
✓. Subject has been diagnosed with Stevens-Johnson syndrome or toxic epidermal necrolysis by at least two dermatologists.
✓. Male or female aged over 20 years old and under 90 years old.

Exclusion criteria

✕. Subject or legally authorized representative is not willing to provide informed consent.
✕. Women who are pregnant or breastfeeding
✕. Subject has an active, untreated, or serious infectious disease that is ineffective in treatment, such as sepsis.
✕. Subject suffers from severe life-threatening cardiac arrhythmia, such as ventricular tachycardia, have had myocardial infarction (myocardial infarction), severe hypertension that has not responded to treatment within the past week, or other cardiologist diagnosed severe cardiovascular disease
✕. Subject has active viral hepatitis
✕. Subject has active tuberculosis
✕. Subject received live vaccination during the illness

What they're measuring

Complete Skin Healing Time, Day, Medium [Full Range]

Timeframe: days

Complete Skin Healing Time, Day, Mean [Full Range]

Timeframe: days

Trial details

NCT IDNCT06474078

SponsorChang Gung Memorial Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-06-20

Results submitted2025-06-20

View on ClinicalTrials.gov More Stevens-Johnson Syndrome trials